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Technologies, and Hormosan. I am an investigator in several clinical trials for 
migraine prevention and acute migraine therapy.
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The genetics of common epilepsies: common or distinct?
In The Lancet Neurology, the International League Against 
Epilepsy Consortium on Complex Epilepsies1 reports 
the ﬁ rst meta-analysis of genome-wide association 
studies (GWAS) in common epilepsies, following a route 
of large-scale collaborations familiar to many other 
groups of chronic diseases. The study brings together 
12 separate datasets from three continents and diverse 
ethnic origins ranging from Chinese to Finnish. The 
analysis poses a philosophical question: can genetic 
factors be identiﬁ ed when the 30 or so diﬀ erent epilepsy 
syndromes are collapsed together or crudely considered 
as generalised or focal types?
The results of the Consortium’s lumping strategy 
to investigate more than 2600 cases of generalised 
epilepsy and 5300 cases of focal epilepsy contain some 
surprises, raise some questions, and will stimulate 
debate about the future of the genetics of common 
epilepsies. Single nucleotide polymorphisms in SCN1A, 
a gene implicated in many diﬀ erent rare epilepsies 
(including Dravet syndrome), emerged as factors 
with genome-wide signiﬁ cance within a dataset that 
included generalised, focal, and unclassiﬁ ed epilepsies. 
Two new candidate loci, one for all epilepsy at 4p15.1 
(possibly implicating a protocadherin, PCDH7) and 
another for genetic generalised epilepsy at 2p16.1, also 
emerged, and await deﬁ nitive gene identiﬁ cation. The 
analysis provides support for the 2p16.1 locus, an earlier 
ﬁ nding by the EPICURE partners for genetic generalised 
epilepsy,2 but no support for another EPICURE genetic 
generalised epilepsy locus at 17q21. Genome-wide 
signiﬁ cance was not attained for single nucleotide 
polymorphisms common to focal epilepsies. 
These results are of most importance for the genetic 
generalised epilepsies, for which ﬁ ndings from genetic 
epidemiological studies have repeatedly shown that 
diﬀ erent generalised epilepsies have high heritability 
and share genetic factors.3 By comparison, focal 
epilepsies have not shown similar levels of heritability,3 
nor has evidence from genetic epidemiological studies 
suggested shared genetic factors (with the exception 
of rare examples such as GRIN2A and DEPDC5 among 
idiopathic and familial focal epilepsies4,5). This meta-
analysis therefore goes some way towards answering 
the question of shared factors, but are we any closer to 
understanding the speciﬁ city of these genes with respect 
to epilepsy subtypes?
GWAS work best when there is little phenotypic, 
ethnic, and allelic heterogeneity in the dataset. Yet 
this meta-analysis forced together diﬀ erent types of 
epilepsy with diﬀ erent case deﬁ nitions from diﬀ erent 
ethnic populations—almost inevitable in retrospective 
collaborations of this size. Heterogeneity can be 
problematic for interpretation of results from genome-
wide analyses. Diﬀ erent eﬀ ect sizes could legitimately 
exist across groups, or eﬀ ect sizes could diﬀ er because 
of diﬀ erent linkage disequilibrium structures (such as 
might be observed in an analysis of individuals with 
mixed ethnic origins). Random-eﬀ ects meta-analyses 
are appropriate in these settings, and can maintain or 
improve power.6 Although assessment is diﬃ  cult in the 
absence of cohort-speciﬁ c QQ-plots, ﬁ ndings from this 
study suggest that the association test statistics might 
deviate from model assumptions; population structure 
could be one explanation, although a mixed model 
framework was used. Other reasons for the possible 
deviations might be the use of linear mixed models for 
a binary outcome, or the choice of a ﬁ xed-eﬀ ects meta-
analysis. The source of this deviation requires some 
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investigation. In any event, there is contribution at the 
identiﬁ ed loci across more than one cohort, but the 
extent and nature of the overall association remains 
unclear.
Heterogeneity is often the price paid for assembly 
of huge sample sizes for GWAS or meta-analyses. 
However, the power of GWAS can be boosted not 
only by increasing sample size, but also in creative 
ways that exploit previous biological knowledge. For 
example, ﬁ ndings from many studies have suggested an 
important role for GABAA receptor function in genetic 
generalised epilepsies,7 and techniques such as genome-
wide pathway and hypothesis-driven analyses8 can be 
exploited to test such speciﬁ c hypotheses and generate 
potential therapeutic targets. Another approach that 
sidesteps the complications of phenotype integrity is the 
use of imaging endophenotypes; changes in structural 
connectivity and grey matter volume have already been 
identiﬁ ed in juvenile myoclonic epilepsy.9 Quantitative 
measures closer to the underlying biology than the clinical 
phenotype might also reduce required sample sizes 
to the hundreds with newly developed mathematical 
methods,10 while improving speciﬁ city of ﬁ ndings. 
Knowledge of the genetics of common epilepsies is in 
need of integration. Strong but rare risk factors in the 
form of recurrent copy-number variation are known, 
and researchers have understood for some time that 
there are distinct genetic inﬂ uences on absence and 
myoclonic seizure types within the genetic generalised 
epilepsies.11 We openly speak of complex models for 
common epilepsies, but recent eﬀ orts have been largely 
in search of rare monogenic causes, or single common 
variants for heterogeneous phenotypic groupings. 
A change in research strategy towards use of more 
speciﬁ c phenotypes (that are guided by family studies 
of phenotype coaggregation in epilepsy syndromes, or 
by endophenotypes), and modelling of complexity in 
studies of the genetic architecture of these phenotypes, 
would serve to reduce heterogeneity and identify 
genes for speciﬁ c syndromes, seizures, and comorbid 
traits. Such studies, hand-in-hand with epigenetics 
and other omics methods, could oﬀ er a way to account 
for individual patient diﬀ erences in presentation, 
comorbidity, and prognosis.
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Lost in space: sleep
Space is one of the most hostile environments. 
Suﬃ  cient sleep duration and quality are crucial to ensure 
performance and prevent fatal errors and accidents in 
space. Data on astronauts’ sleep in space are scarce, but 
in The Lancet Neurology, Laura Barger and colleagues1 
report ﬁ ndings from their study assessing 4267 days of 
actigraphically measured sleep in 85 astronauts during 
Space Shuttle or International Space Station (ISS) missions. 
Sleep averaged 5·96 h (SD 0·56) during shuttle 
missions, 6·09 h (0·67) during ISS missions, and 
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